XML 70 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Equity (Deficit) (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2023 $ 10,397 $ 18 $ (6,533) $ 20,180 $ (1,000) $ (2,305) $ 37
Beginning balance (in shares) at Dec. 31, 2023   1,766          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 4,300 $ 0 0 0 4,300 0 0
Other comprehensive income (loss), net of tax (29) 0 0 0 0 (29) 0
Dividends declared (8,264) 0 0 0 (8,264) 0 0
Purchases of treasury stock (1,350) $ 0 (1,350) 0 0 0 0
Purchases of treasury stock (in shares)   (7)          
Stock-based compensation plans and other 1,015 $ 0 35 980 0 0 0
Stock-based compensation plans and other (in shares)   8          
Change in noncontrolling interest 2 $ 0 0 0 0 0 2
Ending balance at Sep. 30, 2024 6,071 $ 18 (7,848) 21,160 (4,964) (2,334) 39
Ending balance (in shares) at Sep. 30, 2024   1,767          
Beginning balance at Jun. 30, 2024 6,821 $ 18 (7,838) 20,879 (3,768) (2,513) 43
Beginning balance (in shares) at Jun. 30, 2024   1,766          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 1,561 $ 0 0 0 1,561 0 0
Other comprehensive income (loss), net of tax 179 0 0 0 0 179 0
Dividends declared (2,757) 0 0 0 (2,757) 0 0
Purchases of treasury stock (17) $ 0 (17) 0 0 0 0
Purchases of treasury stock (in shares)   0          
Stock-based compensation plans and other 288 $ 0 7 281 0 0 0
Stock-based compensation plans and other (in shares)   1          
Change in noncontrolling interest (4) $ 0 0 0 0 0 (4)
Ending balance at Sep. 30, 2024 6,071 $ 18 (7,848) 21,160 (4,964) (2,334) 39
Ending balance (in shares) at Sep. 30, 2024   1,767          
Beginning balance at Dec. 31, 2024 3,364 $ 18 (8,201) 21,333 (7,900) (1,925) 39
Beginning balance (in shares) at Dec. 31, 2024   1,765          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 2,410 $ 0 0 0 2,410 0 0
Other comprehensive income (loss), net of tax 351 0 0 0 0 351 0
Dividends declared (8,744) 0 0 0 (8,744) 0 0
Purchases of treasury stock (977) $ 0 (977) 0 0 0 0
Purchases of treasury stock (in shares)   (5)          
Stock-based compensation plans and other 993 $ 0 35 958 0 0 0
Stock-based compensation plans and other (in shares)   7          
Change in noncontrolling interest 4 $ 0 0 0 0 0 4
Ending balance at Sep. 30, 2025 (2,599) $ 18 (9,143) 22,291 (14,234) (1,574) 43
Ending balance (in shares) at Sep. 30, 2025   1,767          
Beginning balance at Jun. 30, 2025 (138) $ 18 (9,147) 21,987 (11,503) (1,538) 45
Beginning balance (in shares) at Jun. 30, 2025   1,766          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 186 $ 0 0 0 186 0 0
Other comprehensive income (loss), net of tax (36) 0 0 0 0 (36) 0
Dividends declared (2,917) 0 0 0 (2,917) 0 0
Purchases of treasury stock (4) $ 0 (4) 0 0 0 0
Purchases of treasury stock (in shares)   0          
Stock-based compensation plans and other 312 $ 0 8 304 0 0 0
Stock-based compensation plans and other (in shares)   1          
Change in noncontrolling interest (2) $ 0 0 0 0 0 (2)
Ending balance at Sep. 30, 2025 $ (2,599) $ 18 $ (9,143) $ 22,291 $ (14,234) $ (1,574) $ 43
Ending balance (in shares) at Sep. 30, 2025   1,767